Clinical Trial Update: Effect of a Reduced Dose Enzalutamide in Frail (m)CRPC Patients on Cognitive Side Effects [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating whether a reduced dose of enzalutamide reduces cognitive side effects in frail men with castration-resistant prostate cancer. The study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Xtandi (enzalutamide)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Prostatic Neoplasms, Castration-Resistant | Phase 4 | Status: COMPLETED